Focus: Cogent Biosciences is a public biotech company focused on cellular immunotherapies and targeted oncology treatments, with a diversified pipeline spanning Phase 1 to Phase 3 programs across oncology and neurology indications.
Profile data last refreshed 16m ago · AI intelligence enriched 2mo ago
Cooling — net -8 jobs in 30d
5 added, 13 removed. Slower than typical.
Cogent is a high-risk, high-reward bet suited for scientists and commercial professionals comfortable with pre-revenue biotech dynamics but seeking imminent catalysts; aggressive hiring suggests internal confidence in near-term milestones.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cogent Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cogent Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Cogent Biosciences (COGT) Receives FDA Acceptance for New Drug A - GuruFocus
Cogent Biosciences (COGT) Receives FDA Acceptance for New Drug A GuruFocus
Cogent Biosciences Announces FDA Acceptance of New Drug - GlobeNewswire
Cogent Biosciences Announces FDA Acceptance of New Drug GlobeNewswire
Cancer drug combo halves disease progression risk in GIST trial - Stock Titan
Cancer drug combo halves disease progression risk in GIST trial Stock Titan
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges - MSN
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges MSN
Advanced mastocytosis trial data and JAK2 inhibitor at EHA 2026 - Stock Titan
Advanced mastocytosis trial data and JAK2 inhibitor at EHA 2026 Stock Titan
Cogent Biosciences plans multiple 2026 drug launches, reports $866M cash and Q1 net loss of $97M - Pluang
Cogent Biosciences plans multiple 2026 drug launches, reports $866M cash and Q1 net loss of $97M Pluang
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo